一分钟看懂
这是一项关于小细胞肺癌的I 期研究，登记的药物或干预包括BL-M14D1，当前状态为招募中。登记地点显示中国Huntsville、Glendale、Long Beach、Los Angeles等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BL-M14D1 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Clearview Cancer Institute · Huntsville
- Los Alamitos Hematology/Oncology Medical Group · Glendale
- MemorialCare Long Beach Medical Center · Long Beach
- Valkyrie Clinical Trials · Los Angeles
- UCLA · Los Angeles
- UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center) · San Francisco
- University of Colorado - Anschutz Cancer Pavilion · Aurora
- Yale Cancer Center · New Haven
- Emory Winship · Atlanta
- Tulane School of Medicine · New Orleans
- START - New Jersey · East Brunswick
- John Theurer Cancer Center-Hackensack · Hackensack
- Rutgers Cancer Institute · New Brunswick
- Icahn School of Medicine at Mount Sinai · New York
- Ohio State University · Columbus
- Providence Cancer Institute · Portland
- Prisma Health Cancer Institute · Greenville
- NEXT Dallas · Dallas
- START Dallas- Fort Worth · Dallas
- MD Anderson Cancer Center · Houston
- NEXT Houston · Houston
- START- San Antonio · San Antonio
- NEXT Oncology Virginia · Fairfax
- University of Washington/Fred Hutchinson Cancer Center · Seattle
公开的入选条件
- * Documented locally advanced or metastatic SCLC, large cell neuroendocrine cancer of the lung (LCNEC), neuroendocrine prostate cancer (NEPC), poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) or other extrapulmonary neuroendocri
- Notes: For SCLC, the participant must have failed at least 1 line of platinum therapy in the advanced/metastatic setting.
- No prior topoisomerase inhibitor-based ADC therapy is permitted.
- * In the dose expansion part, Cohort 6 (DLL3-Positive NEN Subgroup): participants will be eligible based on documented positive DLL3 expression.
- * At least one measurable lesion based on RECIST (Response Evaluation Criteria in Solid Tumors) v1.1
- * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1
- * Toxicity of previous antitumor therapy has returned to Grade ≤1 as defined by National Cancer Institute (NCI) CTCAE v5.0, except for alopecia and endocrinopathies controlled by replacement therapy
- * No serious cardiac dysfunction and left ventricular ejection fraction ≥50%
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07080242；登记信息更新于 2026-09-16。